CGEM Latest Headlines

Cullinan Therapeutics: Buy Rating Reaffirmed on Durable CLN-049 AML Responses; $36 Price Target Unchanged

at www.tipranks.com (Wed, 4-Nov 4:05 PM)

Cullinan Shares Updated CLN-049 Phase 1 AML/MDS Data

at www.tipranks.com (Wed, 4-Nov 9:50 AM)

Cullinan Management (CGEM) Receives a Buy from Guggenheim

at www.tipranks.com (Wed, 4-Nov 8:55 AM)

BTIG Reaffirms Their Buy Rating on Cullinan Management (CGEM)

at www.tipranks.com (Mon, 2-Nov 9:43 PM)

CGEM Sets Up a Data-Heavy Q4 2026 With Three T Cell Engager Readouts Across Autoimmune Disease and AML

Market Chameleon (Thu, 24-Sep 11:47 AM)

Cullinan Therapeutics spotlights pipeline strategy in a Sept. 24 Stifel virtual fireside chat

Market Chameleon (Tue, 22-Sep 9:46 AM)

CGEM’s Zipalertinib Trial Meets Key Progression-Free Survival Mark, Paving Way for Possible FDA Filing

Market Chameleon (Thu, 13-Aug 7:30 AM)